Kirsten Van Camp
Overview
Explore the profile of Kirsten Van Camp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van den Bossche J, De Laere M, Deschepper K, Germonpre P, Valcke Y, Lamont J, et al.
PLoS One
. 2024 Jul;
19(7):e0307204.
PMID: 39008481
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing...
2.
Wouters R, Van Camp K
Int J Press Polit
. 2017 Oct;
22(4):450-470.
PMID: 29081881
Demonstration turnout is a crucial political resource for social movements. In this article, we investigate how mass media cover demonstration size. We develop a typology of turnout coverage and scrutinize...
3.
Van Craenenbroeck A, Smits E, Anguille S, Velde A, Stein B, Braeckman T, et al.
Transplantation
. 2014 Jul;
99(1):120-7.
PMID: 25050468
Background: Infection with human cytomegalovirus (CMV) is a significant cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients. Methods: The present study explored the...
4.
Cools N, Van Camp K, Van Tendeloo V, Berneman Z
Methods Mol Biol
. 2013 Jan;
969:293-303.
PMID: 23296941
Monitoring the immune response is an essential aspect of numerous clinical vaccination trials in order to evaluate the efficacy. In these clinical vaccination trials, peripheral blood mononuclear cells (PBMC) are...
5.
Smits E, Cools N, Lion E, Van Camp K, Ponsaerts P, Berneman Z, et al.
Cancer Immunol Immunother
. 2009 May;
59(1):35-46.
PMID: 19449004
Immunotherapy for leukemia is a promising targeted strategy to eradicate residual leukemic cells after standard therapy, in order to prevent relapse and to prolong the survival of leukemia patients. However,...